| Original language | English |
|---|---|
| Pages (from-to) | 981-983 |
| Number of pages | 3 |
| Journal | Journal of Diabetes Investigation |
| Volume | 9 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 07-2018 |
| Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes : The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation. / Usui, Ryota; Sakuramachi, Yui; Seino, Yusuke; Murotani, Kenta; Kuwata, Hitoshi; Tatsuoka, Hisato; Hamamoto, Yoshiyuki; Kurose, Takeshi; Seino, Yutaka; Yabe, Daisuke.
In: Journal of Diabetes Investigation, Vol. 9, No. 4, 07.2018, p. 981-983.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Reply to the comment of Wilbrink et al. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes
T2 - The association between remaining β-cell function and the achievement of the HbA1c target 1 year after initiation
AU - Usui, Ryota
AU - Sakuramachi, Yui
AU - Seino, Yusuke
AU - Murotani, Kenta
AU - Kuwata, Hitoshi
AU - Tatsuoka, Hisato
AU - Hamamoto, Yoshiyuki
AU - Kurose, Takeshi
AU - Seino, Yutaka
AU - Yabe, Daisuke
N1 - Funding Information: Daisuke Yabe received consulting or speaker fees from MSD K.K., Novo Nor disk Pharma Ltd., Takeda Pharmaceutical Company Limited and Taisho Toyama Pharmaceutical Co. Ltd. Daisuke Yabe also received clinically commissioned/ joint research grants from Nippon Boeh ringer Ingelheim Co., Ltd., Eli Lilly and Company, Taisho Toyama Pharmaceutical Co. Ltd., MSD K.K., Ono Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., Arklay Co. Ltd., and Takeda Pharmaceutical Company Limited. Yoshiyuki Hamamoto received consulting or speaker fees from Novo Nordisk Pharma Ltd. Takeshi Kurose received consulting or speaker fees from Sanofi K.K. Takeshi Kurose also received clinically commissioned/joint research grants from the Japan Vascular Disease Research Foundation. Yutaka Seino received consulting or speaker fees from Eli Lilly Japan K.K., Sanofi K.K., Novo Nordisk Pharma Inc., Glaxo-Smith-Kline, Taisho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Astellas Pharma Inc., BD, Nippon Boehringer Ingelheim Co., Ltd., Johnson & Johnson and Takeda Pharmaceutical Company Limited. Yutaka Seino also received clinically commissioned/joint research grants from Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly and Company, Taisho Toyama Pharmaceutical Co. Ltd., MSD K.K., Ono Pharmaceutical Co. Ltd., Novo Nordisk Pharma Ltd., and Arklay Co. Ltd. R. The other authors declare no conflict of interest.
PY - 2018/7
Y1 - 2018/7
UR - http://www.scopus.com/inward/record.url?scp=85050007955&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050007955&partnerID=8YFLogxK
U2 - 10.1111/jdi.12858
DO - 10.1111/jdi.12858
M3 - Letter
C2 - 29974670
AN - SCOPUS:85050007955
VL - 9
SP - 981
EP - 983
JO - Journal of Diabetes Investigation
JF - Journal of Diabetes Investigation
SN - 2040-1116
IS - 4
ER -